PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc has granted 1,008,068,322 share options to Chief Executive Officer Richard Compton under its 2016 Employee Share Option Plan. These options are split into three tranches of 336,022,774 each, with exercise prices of 0.115 pence, 0.1725 pence, and 0.23 pence, vesting over twelve equal tranches between one and thirty-six months from the grant date. Following this grant, Richard Compton's interest will comprise 300,000,000 shares, representing 2.23% of the current issued share capital, and 1,008,068,322 options, representing 7.50% of the current issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
Oxford BioDynamics Plc (AIM: OBD, the Company), the 3D Genomics Company, announces that it has today granted a total of 1,008,068,322 options (“Options”) over its ordinary shares of 0.1 pence each (“Ordinary Shares”), to Chief Executive Officer Richard Compton.
The options were granted under the Company’s 2016 Employee Share Option Plan with exercise prices and vesting dates as shown in the table below.
| Number of options | Exercise price (p) | Premium over closing mid-market price on 17 September 2026 | Vesting dates |
|---|---|---|---|
| 336,022,774 | 0.115 | - | 12 equal tranches, one month to twelve months from today’s date |
| 336,022,774 | 0.1725 | 50% | 12 equal tranches, between 13 and 24 months from today’s date |
| 336,022,774 | 0.23 | 100% | 12 equal tranches, between 25 and 36 months from today’s date |
Options will be exercisable at any time from 18 September 2027 upon vesting. Thereafter, the Options, once vested, will remain exercisable up to and including the tenth anniversary of the date of grant.
Following the grant of Options, Richard Compton’s interest in the Company will comprise:
| Shareholding | Percentage of current issued share capital | Option of over Ordinary Shares | Percentage of current issued share capital |
|---|---|---|---|
| 300,000,000 | 2.23% | 1,008,068,322 | 7.50% |
The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Richard Compton |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/ Amendment | Initial notification |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1 pence each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Grant of share options |
| c) | Price(s) and volume(s) | 336,022,774 ordinary shares at an exercise price of 0.115 pence per share 336,022,774 ordinary shares at an exercise price of 0.1725 pence per share 336,022,774 ordinary shares at an exercise price of 0.23 pence per share |
| d) | Aggregated information - Aggregated volume - Price | N/A |
| e) | Date of the transaction | 18 September 2026 |
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.